FDA Approves First Menin Inhibitor for Relapsed, Refractory Acute Leukemia With KMT2A Translocation
Melissa BadamoAcute Myeloid Leukemia | November 19, 2024

The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%, a median duration of CR+CRh of 6.4 months, and a median time to CR or CRh of 1.9 months.

Advertisement
Advertisement

Advertisement
Advertisement
Editorial Board

Podcasts

Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Listen Now
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Mazyar Shadman, MD, MPHThe HemOnc Pulse | September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 17, 2024
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Afaf Osman, MDThe HemOnc Pulse | August 9, 2024
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 26, 2024
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 16, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.

Video Insights

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

Network Websites